The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC).




Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer

Sponsored by Internet Pharmacy - Indian Pharmacy, an online pharmacy supplies more than 600 quality generic medications, free prescription, worldwide shipping.

Canadian Pharmacy canada pharmacy

Related posts:

  1. FDA Approves Tarceva As A Maintenance Therapy For Advanced Non-Small Cell Lung Cancer OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and drug Administration (FDA) approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced...
  2. NICE Recommends Gefitinib For Non Small Cell Lung Cancer In draft guidance, published today (27 May 2010) NICE recommends gefitinib (Iressa) as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer if...
  3. Poniard Pharmaceuticals Announces Results Of Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced that data from the Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial evaluating the...